![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. Agerite Alba
2. Benoquin
3. Hydroquinone Monobenzyl Ether
4. Monobenzyl Ether Hydroquinone
5. Novo-depigman
6. P-(benzyloxy)phenol
1. 4-benzyloxyphenol
2. 103-16-2
3. 4-(benzyloxy)phenol
4. Hydroquinone Monobenzyl Ether
5. Benoquin
6. Benzoquin
7. P-(benzyloxy)phenol
8. Monobenzyl Hydroquinone
9. Leucodinine
10. Monobenzon
11. Superlite
12. Agerite Alba
13. Hydroquinone Benzyl Ether
14. Dermochinona
15. Carmifal
16. Depigman
17. 4-(phenylmethoxy)phenol
18. Pigmex
19. P-hydroxyphenyl Benzyl Ether
20. Alba-dome
21. Benzyl P-hydroxyphenyl Ether
22. Monobenzyl Ether Hydroquinone
23. 4-(benzyloxyl)phenol
24. Agerite
25. Benzyl Hydroquinone
26. Phenol, 4-(phenylmethoxy)-
27. Monobenzone [inn]
28. 4-phenylmethoxyphenol
29. Monobenzonum
30. Monobenzona
31. Monobenzonum [inn-latin]
32. Monobenzona [inn-spanish]
33. Superlite (antioxidant)
34. Alba
35. Hydrochinon Monobenzylether [czech]
36. P-benzyloxyphenol
37. Phenol, P-(benzyloxy)-
38. Hydrochinon Monobenzylether
39. Monobenzyl Ether Of Hydroquinone
40. 4-phenylmethoxy-phenol
41. Nsc 2132
42. Mfcd00002333
43. 4-benzyloxy-phenol
44. Monobenzone (benoquin)
45. Nsc-2132
46. 4-benzyloxy Phenol
47. 9l2ka76mg5
48. Pbp
49. Chebi:34380
50. Ncgc00016360-01
51. Cas-103-16-2
52. Dsstox_cid_717
53. Hydroquinone Monobenzylether
54. Wln: Qr Do1r
55. Dsstox_rid_75755
56. Dsstox_gsid_20717
57. Benoquin (tn)
58. Hsdb 4019
59. Sr-05000001819
60. Monobenzone (usp/inn)
61. Monobenzone [usp:inn]
62. Einecs 203-083-3
63. Brn 1958305
64. Unii-9l2ka76mg5
65. 4-benzoxyphenol
66. Ai3-14325
67. 4-benzyloxylphenol
68. P-benzyloxy Phenol
69. P-benzyloxy-phenol
70. Monobenzone, Usp
71. 4(benzyloxy)phenol
72. (p)-benzyloxyphenol
73. 4-(benzyloxy)-phenol
74. Para-(benzyloxy)phenol
75. Monobenzone [mi]
76. Prestwick0_000912
77. Prestwick1_000912
78. Prestwick2_000912
79. Prestwick3_000912
80. Monobenzone [hsdb]
81. Monobenzone [vandf]
82. Chembl1388
83. Monobenzone [mart.]
84. Oprea1_698781
85. Schembl35631
86. Bspbio_000784
87. Monobenzone [usp-rs]
88. Monobenzone [who-dd]
89. 4-(benzyloxy)phenol, 98%
90. 4-06-00-05728 (beilstein Handbook Reference)
91. Bidd:er0003
92. Spbio_002973
93. Bpbio1_000864
94. Gtpl6830
95. Zinc1748
96. Dtxsid2020717
97. 4-(benzyloxy)phenol, >=99%
98. Monobenzone [orange Book]
99. Nsc2132
100. Hms1570h06
101. Hms1580p12
102. Hms2097h06
103. Hms3655k15
104. Hms3714h06
105. Pharmakon1600-01503031
106. Monobenzone [usp Monograph]
107. Act04723
108. Bcp09974
109. Cs-b0870
110. Nsc33918
111. Tox21_110396
112. Tox21_201147
113. Bdbm50410520
114. Nsc-33918
115. Nsc758211
116. S1652
117. Stl283939
118. Akos000119555
119. Tox21_110396_1
120. Ac-2492
121. Ccg-213094
122. Db00600
123. Nsc-758211
124. Ps-8213
125. Ncgc00016360-02
126. Ncgc00016360-03
127. Ncgc00016360-05
128. Ncgc00016360-06
129. Ncgc00258699-01
130. Hy-30272
131. Sy001650
132. Ab00513959
133. Am20020110
134. Ft-0616695
135. Sw197310-3
136. D05072
137. F11201
138. Ab00513959-03
139. Ab00513959_04
140. Ab00513959_05
141. 103h162
142. A800687
143. Q-200440
144. Q2768526
145. Sr-05000001819-1
146. Sr-05000001819-2
147. Sr-05000001819-3
148. Brd-k54262262-001-01-7
149. Brd-k54262262-001-06-6
150. F0777-0782
151. Z199511588
152. Monobenzone, United States Pharmacopeia (usp) Reference Standard
153. 4-(benzyloxy)phenol ; Hydroquinone Monobenzyl Ether ; Pbp ; Monobenzone
Molecular Weight | 200.23 g/mol |
---|---|
Molecular Formula | C13H12O2 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 200.083729621 g/mol |
Monoisotopic Mass | 200.083729621 g/mol |
Topological Polar Surface Area | 29.5 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 167 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
MONOBENZONE, MONOBENZYL ETHER OF HYDROQUINONE, IS AMELANOTIC AGENT USED IN SEVERE FRECKLING & OTHER CONDITIONS CHARACTERIZED BY HYPERPIGMENTATION OF SKIN.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 954
IT IS APPLIED TO HYPERPIGMENTED AREAS 2 OR 3 TIMES DAILY FOR UP TO 4 MO, OR UNTIL DEPIGMENTATION HAS OCCURRED, & THEN TWICE WEEKLY TO MAINTAIN EFFECT. ... IF SATISFACTORY RESPONSE IS NOT OBSERVED WITHIN 4 MO, TREATMENT SHOULD BE DISCONTINUED.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 955
...POSSIBLY EFFECTIVE FOR TREATMENT OF HYPERPIGMENTATION CAUSED BY EXCESSIVE FORMATION OF MELANIN, SUCH AS OCCURS IN GENERALIZED LENTIGO...MELASMA OF PREGNANCY, & HYPERPIGMENTATION FOLLOWING INFLAMMATION OF SKIN.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 955
VITILIGO PATIENTS USED 20% MONOBENZONE 2 TIMES/DAY UNTIL DEPIGMENTATION; THOSE ACHIEVING COMPLETE DEPIGMENTATION WERE TREATED FOR 10 MO OR MORE. DEPIGMENTATION INDUCED BY MONOBENZONE IS GENERALLY IRREVERSIBLE.
MOSHER ET AL; BR J DERMATOL 97 669-679 (DEC 1977)
For more Therapeutic Uses (Complete) data for P-(BENZYLOXY)PHENOL (6 total), please visit the HSDB record page.
TREATED AREAS SHOULD NOT BE EXPOSED TO SUNLIGHT; ULTRAVIOLET LIGHT NEUTRALIZES DEPIGMENTING EFFECT.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 955
MONOBENZONE THERAPY IS OFTEN DIFFICULT TO MANAGE & REQUIRES CAREFUL PT FOLLOW-UP; IT CAN PRODUCE BIZARRE PATTERNS, WITH HYPOPIGMENTATION @ SITES DISTANT FROM AREA OF APPLICATION.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 911
...SHOULD ONLY BE USED TO PERMANENTLY REMOVE REMAINING AREAS OF NORMAL PIGMENTATION IN PT WITH DISSEMINATED VITILIGO. ...NOT RECOMMENDED IN TREATMENT OF MELASMA OR POSTINFLAMMATORY & OTHER TYPES OF HYPERPIGMENTATION. ...MAY CAUSE HYPERSENSITIVITY REACTIONS.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 911
SINCE DRUG DOES NOT DESTROY MELANOCYTES OR FACILITATE LOSS OF PREVIOUSLY SYNTHESIZED MELANIN, RESPONSE TO THERAPY IS USUALLY NOT APPARENT UNTIL 1-4 MO. ... UNLESS CAREFULLY APPLIED, UNSIGHTLY DEPIGMENT PATCHES MAY RESULT FROM ITS USE.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 955
Used topically to treat the loss of skin color (vitiligo).
FDA Label
Monobenzone is the monobenzyl ether of hydroquinone. Monobenzone, applied topically to the skin, is used as a depigmenting agent inhibitting melanin produced by polymerization of oxidation products of tyrosine and dihydroxyphenyl compounds. Monobenzone works by permanently removing color from normal skin located around skin with vitiligo.
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AX - Other dermatologicals
D11AX13 - Monobenzone
... Predicted by its low chronic toxicity ... hydroquinone monobenzyl ether may readily be metabolized in the same manner as phenol.
Clayton, G. D. and F. E. Clayton (eds.). Patty's Industrial Hygiene and Toxicology: Volume 2A, 2B, 2C: Toxicology. 3rd ed. New York: John Wiley Sons, 1981-1982., p. 2532
Monobenzone is a depigmenting agent whose mechanism of action is not fully understood. It is proposed that it increases the excretion of melanin from the melanocytes. This effect is erratic and may take one to four months to occur while existing melanin is lost with normal sloughing of the stratum corneum. Hyperpigmented skin appears to fade more rapidly than does normal skin, and exposure to sunlight reduces the depigmenting effect of the drug. Following skin depigmentation after topical application of monobenzone, the histological studies indicate similar results as that seen in vitiligo, where the epidermis is intact but with the absence of identifiable melanocytes.
...INTERFERES WITH BIOSYNTHESIS OF MELANIN. IT INHIBITS ENZYME TYROSINASE & THEREBY PREVENTS CONVERSION OF TYROSINE TO DIHYDROXYPHENYLALANINE, PRECURSOR OF MELANIN.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 955